Ameet Kumar Mishra

Ameet Kumar Mishra

Auto-generated profile, based on publicly available information

Ameet Kumar Mishra

Genentech 6 , San Francisco, California

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 November 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
AMAmeet K. Mishra
Ameet K. Mishra
TKTanya Kadoishi
Tanya Kadoishi
XWXiaoguang Wang
Xiaoguang Wang
EDEmily Driver
Emily Driver
ZCZhangguo Chen
Zhangguo Chen
Jing WangJing Wang
Jing Wang
Oncotarget | https://doi.org/10.18632/oncotarget.13228 Ameet K. Mishra, Tanya Kadoishi, Xiaoguang Wang, Emily Driver, Zhangguo Chen, Xiao-Jing Wang, Jing H. Wang Squamous cell carcinomas escape immune surveillance via inducing chronic activation and exhaustion of CD8+ T Cells co-expressing PD-1 and LAG-3 inhibitory receptors


25 May 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AMAmeet K Mishra
Ameet K Mishra
CPChristopher Parish
Christopher Parish
MWMa-Li Wong
Ma-Li Wong
JLJulio Licinio
Julio Licinio
ABAnneke Blackburn
Anneke Blackburn
Epidemiological studies have shown obesity to be linked with poorer outcomes in breast cancer patients. The molecular mechanisms responsible for the increased risk of invasive/metastatic disease with obesity are complex, but may include elevated levels of adipokines such as leptin. Using physiological levels of leptin found in obesity in a novel chronic in vitro treatment model (≤200 ng/ml for 14 days), we confirmed the occurrence of leptin-mediated changes in growth, apoptosis and metastatic behavior, and gene expression changes representing epithelial-to-mesenchymal transition (EMT) and a cancer stem cell (CSC) like phenotype in breast epithelial and cancer cell lines (MCF10A, MCF10AT1, MCF7 and MDA-MB-231). Further, we have discovered that these effects were accompanied by increased expression of TGFB1, and could be significantly reduced by co-treatment with neutralizing antibody against TGFB1, indicating that the induction of these characteristics was mediated via TGFB1. Occurring in both MCF7 and MCF10AT1 cells, it suggests these actions of leptin to be independent of estrogen receptor status. By linking leptin signalling to the established TGFB1 pathway of metastasis / EMT, this study gives a direct mechanism by which leptin can contribute to the poorer outcomes of obese cancer patients. Inhibitors of TGFB1 are in currently in phase III clinical trials in other malignancies, thus identifying the connection between leptin and TGFB1 will open new therapeutic opportunities for improving outcomes for obese breast cancer patients.

28 July 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
AMAmeet K. Mishra
Ameet K. Mishra
AAAnnelie Abrahamsson
Annelie Abrahamsson
CDCharlotta Dabrosin
Charlotta Dabrosin
Fulvestrant inhibits growth of triple negative breast cancer and synergizes with tamoxifen in ERa positive breast cancer by up-regulation of ERβ

4 January 2021 in Blood Cancer Journal
Verified
Journal Article
Open access
PDF file
AMAmeet K. Mishra
Ameet K. Mishra
IKIris Kemler
Iris Kemler
David Dingli, MD PhDDavid Dingli, MD PhD
David Dingli, MD PhD
Chimeric antigen receptor T (CAR-T) cell therapy is a transformative approach to cancer eradication. CAR-T is expensive partly due to the restricted use of each CAR construct for specific tumors. Thus, a CAR construct with broad antitumor activity can be advantageous. We identified that CD126 is expressed by many hematologic and solid tumors, including multiple myeloma, lymphoma, acute myeloid leukemia, pancreatic and prostate adenocarcinoma, non-small cell lung cancer, and malignant melanoma among others. CAR-T cells targeting CD126 were generated and shown to kill many tumor cells in an antigen-specific manner and with efficiency directly proportional to CD126 expression. Soluble CD126 did not interfere with CAR-T cell killing. The CAR-T constructs bind murine CD126 but caused no weight loss or hepatotoxicity in mice. In multiple myeloma and prostate adenocarcinoma xenograft models, intravenously injected CD126 CAR-T cells infiltrated within, expanded, and killed tumor cells without toxicity. Binding of soluble interleukin-6 receptor (sIL-6R) by CAR-T cells could mitigate cytokine release syndrome. Murine SAA-3 levels were lower in mice injected with CD126 CAR-T compared to controls, suggesting that binding of sIL-6R by CAR-T cells could mitigate cytokine release syndrome. CD126 provides a novel therapeutic target for CAR-T cells for many tumors with a low risk of toxicity.

14 November 2023 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
AMAmeet K. Mishra
Ameet K. Mishra
TSTimothy M. Schmidt
Timothy M. Schmidt
EMElla B. Martell
Ella B. Martell
ACAlex S. Chen
Alex S. Chen
RDReyna E. Dogru
Reyna E. Dogru
NCNatalie Callander
Natalie Callander
Chimeric antigen receptor (CAR-T) cell therapy has shown rapid, frequent and deep responses in patients with relapsed, refractory multiple myeloma (RRMM). However, relapse following CAR-T is frequently observed and the cause for resistance is not well defined. Among the potential mechanisms of resistance, T cell intrinsic factors may be an important source of failure. Here, we used spectral flow cytometry to identify the change in T cell phenotypes in bone marrow aspirates at different stages of multiple myeloma progression, including cases that relapsed after anti-BCMA CAR-T therapies. We identified completely different T cell phenotypes in RRMM and post CAR-T relapse cases compared to healthy donors and earlier stages of multiple myeloma, a novel double negative CD3+ T cells in RRMM and CAR-T relapsed cases, and difference in CD8 T cell phenotype at the baseline between peripheral blood and bone marrow from healthy donors. We found that the majority of T cells in RRMM, and significant subset of T cells in post CAR-T relapsed cases, expressed multiple co-inhibitory markers including PD1, TIGIT, 2B4 and KLRG1.